Amgen Working With Payors To Identify NESP Patients At Primary Care Level

Amgen is working with payors to identify chronic renal insufficiency patients in the primary care market who may be candidates for therapy with the Epogen successor product Aranesp, the company told securities analysts in New York City Nov. 8.